Table 2. Patients included in the analysis of versican expression.
| Clinical characteristics | All patients [n = 74] | All stable [n = 58] | Stable w/o ARF[n = 53] | Progressive [n = 16] | p * | p ** |
| Sex (m/f) | 49/25 | 36/22 | 33/20 | 13/3 | NA | NA |
| Age (years) | 48±16 | 48±17 | 48±17 | 47±14 | n.s. | n.s. |
| Biopsy creatinine (mg/dl) | 1.89±1.47 | 1.76±1.45 | 1.42±0.88 | 2.37±1.48 | n.s. | 0.003 |
| Biopsy proteinuria (g/g) | 3.46±3.35 | 3.42±3.63 | 3.62±3.72 | 3.61±2.00 | n.s. | n.s. |
| Follow up time (months) | 53±22 | 55±20 | 55±20 | 45±27 | n.s. | n.s. |
| Endpoint: ESRD | 12 | 0 | 0 | 12 | NA | NA |
| Endpoint: Doubling creatinine | 4 | 0 | 0 | 4 | NA | NA |
| Follow up creatinine (mg/dl) | 2.51±2.62 | 1.34±0.72 | 1.34±0.74 | 6.76±2.64 | <0.001 | <0.001 |
| Follow up proteinuria (g/g) | 1.27±1.78 | 0.65±0.79 | 0.67±0.80 | 3.43±2.43 | <0.001 | <0.001 |
| Diagnosis | ||||||
| DN | 3 | 1 | 1 | 2 | NA | NA |
| HTN | 7 | 4 | 3 | 3 | NA | NA |
| IGAN | 19 | 13 | 12 | 6 | NA | NA |
| MCD | 10 | 10 | 10 | 0 | NA | NA |
| FSGS | 7 | 5 | 5 | 2 | NA | NA |
| Vasculitis | 6 | 6 | 5 | 0 | NA | NA |
| MN | 8 | 5 | 5 | 3 | NA | NA |
| IN | 4 | 4 | 3 | 0 | NA | NA |
| LN | 2 | 2 | 2 | 0 | NA | NA |
| MPGN | 2 | 2 | 2 | 0 | NA | NA |
| Goodpasture | 2 | 2 | 1 | 0 | NA | NA |
| other | 3 | 3 | 3 | 0 | NA | NA |
| RPGN | 1 | 1 | 1 | 0 | NA | NA |
ESRD end-stage renal disease, 2 x creatinine doubling of serum creatinine. Proteinuria was measured as protein/creatinine ratio in g/g. Mean values and standard deviations are shown. Differences between the means were analyzed by a two-tailed t-test. n.s. not significant (p>0.05), NA not applicable. For abbreviation of the histological diagnosis see the Experimental Procedures section. ARF Acute Renal Failure. * all stable vs progressive. ** stable w/o ARF vs progressive.